<DOC>
	<DOCNO>NCT00604539</DOCNO>
	<brief_summary>The purpose study determine effect chondroitin sulphate conventional treatment degree severity synovitis , measure magnetic resonance patient knee OA clinical synovitis .</brief_summary>
	<brief_title>Effect Chondroitin Sulphate Synovial Inflammation Patients With Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Synovitis</mesh_term>
	<criteria>Primary OA knee accord ACR synovitis criterion ( warmth , swell effusion ) ; OA radiological stage 2 3 accord KellgrenLawrence ; Minimum joint space width ≥2 mm medial femorotibial compartment stand knee Xray ; VAS pain walk ≥40 mm . Known allergy chondroitin sulphate ; Progressive serious pathology ( cancer , AIDS , ... ) ; Other bone articular disease ( antecedent and/or current sign ) chondrocalcinosis , Paget 's disease , rheumatoid arthritis , aseptic osteonecrosis , gout , septic arthritis , ochronosis , acromegaly , hemochromatosis , Wilson 's disease , osteochondromatosis ; Corticosteroids ( oral , injectable ) , indomethacin , therapeutic dose glucosamine chondroitin sulphate 12 week precede inclusion ; Hyaluronic Acid ( intraarticular pathway ) 26 week precede inclusion ; Radioactive synovectomy 12 week precede inclusion ; If patient receiving NSAID baseline ( D0 ) , maintain stable dosage much possible D0 D180 . In open phase study ( D180 D360 ) , NSAID also allow rescue medication along acetaminophen .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Chondroitin sulphate</keyword>
	<keyword>Synovitis</keyword>
	<keyword>Knee osteoarthritis</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
</DOC>